Eliquis: Bristol-Myers Squibb’s Cardiovascular Blockbuster in 4Q17
BMY’s cardiovascular portfolio
Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes Eliquis, one of the company’s best-selling products. The chart below compares the revenues for Eliquis since 1Q16.
Interested in BMY? Don't miss the next report.
Receive e-mail alerts for new research on BMY
Eliquis is a factor Xa inhibitor approved for the prevention of stroke in patients with non-valvular atrial fibrillation and for the prevention of venous thromboembolism disorders. The drug is developed in collaboration with Pfizer (PFE).
Eliquis reported revenues of ~$1.4 billion during 4Q17 for revenue growth of ~44.0%. In comparison to its reported revenues of $948.0 million during 4Q16. Eliquis reported sales of $768.0 million during 4Q17 from the US markets, representing an increase of more than 42.0% compared to sales of $539.0 million during 4Q16.
Eliquis’s US sales increased due to strong demand for the drug during 4Q17. Its international sales also reported positive growth due to the increase in demand.
For fiscal 2017, Eliquis reported revenues of ~$4.9 billion, representing growth of ~46.0% in revenues compared to revenues of $3.3 billion during 2016. Eliquis reported sales of ~$2.9 billion during fiscal 2017 from the US markets. Its fiscal 2017 was an increase of more than 47.0% compared to sales of ~$2.0 billion during 2016.
The growth in the drug’s US sales was due to increase in demand for the drug, as the drug is approved for a large number of indications.
Bristol-Myers Squibb (BMY) is focused on the development of new cardiovascular drugs. These drugs are intended for unmet needs related to cardiovascular diseases like arrhythmia, atherosclerosis, atrial fibrillation, heart failure, and thrombosis.